Publications by authors named "Maria Kinberger"

In 1997 rituximab, a genetically engineered chimeric monoclonal antibody (mAb) targeting CD20 expressed on B cells was approved for treatment of non-Hodgkin's lymphoma. Since then, pharmacological improvements combined with increased knowledge on the immunopathogenesis of diseases led to the development of specific mAb targeting different antigens (e.g.

View Article and Find Full Text PDF
Article Synopsis
  • A new guideline for atopic eczema was published in two parts in August and September 2022, based on the EuroGuiDerm standards, following extensive consensus conferences with experts from twelve European countries.
  • The guideline incorporates recent evidence on new systemic medications, with an update released in October 2022.
  • Italian dermatological societies adapted the original EuroGuiDerm guideline for the Italian healthcare context, adding specific notes to highlight regulations and recommendations from the Italian Ministry of Health and regional authorities.
View Article and Find Full Text PDF

SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by atopic dermatitis. The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual.

View Article and Find Full Text PDF
Article Synopsis
  • - SIDeMaST developed guidelines for treating chronic plaque psoriasis and adapted them for the Italian healthcare system, aiming to provide a dependable resource for doctors treating atopic dermatitis patients in Italy.
  • - The guideline follows the EuroGuiDerm Manual and was created with the input of 29 experts from 12 European countries, involving four consensus conferences held between December 2020 and July 2021.
  • - It includes comprehensive information on systemic therapies, discussing conventional immunosuppressants, biologics, and Janus kinase inhibitors, while the second part will focus on factors like diet, immunotherapy, and considerations for special patient groups.
View Article and Find Full Text PDF

Background: Cases of mpox have been reported worldwide since May 2022. Limited knowledge exists regarding the long-term course of this disease. To assess sequelae in terms of scarring and quality of life (QoL) in mpox patients 4-6 months after initial infection.

View Article and Find Full Text PDF

The updated S2k guideline deals with the diagnosis and therapy of localized scleroderma (LoS). LoS represents a spectrum of sclerotic skin diseases in which, depending on the subtype and localisation, structures such as adipose tissue, muscles, joints, and bones may also be affected. Involvement of internal organs or progression to systemic sclerosis does not occur.

View Article and Find Full Text PDF

This S3 guideline was created based on the European S3 guideline, with special consideration of the medical conditions in the German-speaking region and incorporating additions from the previous German-language version. The interdisciplinary guideline commission consisted of representatives from the German Dermatological Society, the Professional Association of German Dermatologists, the Austrian Society of Dermatology and Venereology, the Swiss Society of Dermatology and Venereology, the German Society for Allergology and Clinical Immunology, the German Society for Pediatric and Adolescent Medicine, the Professional Association of Pediatricians and Adolescent Medicine, the Society for Pediatric Allergology and Environmental Medicine, the German Society for Pediatric Rehabilitation and Prevention, the German Society for Psychosomatic Medicine and Medical Psychotherapy, the German Network for Health Services Research, the German Eczema Association and the German Allergy and Asthma Association. This first part of the guideline focuses on the definition and diagnostic aspects of atopic dermatitis (AD), addressing topical therapy as well as non-pharmacological treatment approaches such as UV therapy, psychoeducational therapy, dietary interventions for AD, allergen immunotherapy for AD, and complementary medicine.

View Article and Find Full Text PDF

The present S3 guideline was created based on the European English-language S3 guideline, with special consideration given to the medical conditions in the German-speaking region, and with additions from the previous German-language version, in accordance with the criteria of the AWMF. This second part of the guideline addresses the systemic therapy of atopic dermatitis (AD). It covers topics such as the indication for systemic therapy in children, adolescents, and adult patients with AD.

View Article and Find Full Text PDF

Background: Anogenital disorders encompass a broad spectrum of conditions with diverse pathogenetic origins, often presenting with nonspecific symptoms and overlapping causative factors, thereby posing diagnostic and therapeutic challenges. Effective management requires interdisciplinary knowledge and the use of medical guidelines. Guidelines can play an important role in translating current knowledge into clinical practice and ensuring consistent care, minimizing complications, and optimizing patient outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Psoriasis is a chronic immune-mediated disease affecting skin and/or joints, significantly impacting quality of life, with no known cure but manageable through various treatments.
  • This study aimed to evaluate and rank the effectiveness and safety of non-biological systemic agents, small molecules, and biologics for moderate-to-severe psoriasis using a network meta-analysis approach.
  • Researchers analyzed data from randomized controlled trials, focusing on the percentage of participants achieving nearly clear skin and the occurrence of serious side effects, to determine the relative benefits and harms of different treatment options.
View Article and Find Full Text PDF
Article Synopsis
  • The updated S2k guideline focuses on the diagnosis and treatment of rosacea, a common chronic skin disease primarily affecting the face, with symptoms evolving from flushing to severe inflammatory lesions.
  • Treatment recommendations include avoiding triggers and using topical treatments like metronidazole, azelaic acid, and ivermectin; vasoconstrictors for persistent redness; and systemic therapy for severe cases, primarily low-dose doxycycline.
  • Additional care for ocular rosacea involves lid hygiene and treatments such as ciclosporin eye drops and azithromycin.
View Article and Find Full Text PDF

The group of granulomatous dermatoses refers to a multitude of clinically different diseases, which are characterized by a histopathologically similar pattern of inflammation. The cause of granulomatous inflammatory reactions can be infections and also noninfectious stimuli, such as cell disintegration or foreign bodies. The aim of this immunological defence reaction is encapsulation in order to prevent further spread and delimitation from healthy tissue.

View Article and Find Full Text PDF

Background: Melasma is a common dermatological condition. Although its relevance as a skin condition is primarily of a cosmetic nature, it may affect the patient's wellbeing and quality of life. A broad range of treatment options is available, which makes it difficult to choose the most appropriate of those treatments.

View Article and Find Full Text PDF